Ovarian Cancer
A cancer arising in the ovaries that often presents at an advanced stage, where specialist surgical and medical oncology coordination meaningfully shapes outcomes.
- Specialist Surgical Review
- BRCA and Biomarker Testing
- Access to PARP Inhibitor Therapy
- Clinical Trial Access
- Most Common In
- Postmenopausal Women
- Most Common Subtype
- High-Grade Serous Carcinoma
- Key Biomarker
- BRCA1/BRCA2 Mutation Status
- Advanced Therapies
- PARP Inhibitors, Bevacizumab, Immunotherapy Trials
Condition Overview
Ovarian cancer arises from cells within or near the ovary and includes several distinct subtypes with different cells of origin, molecular features, and treatment approaches. The most common and clinically significant form, high-grade serous carcinoma, is now understood in many cases to originate in the fallopian tube before spreading to the ovary and surrounding pelvic structures.
Ovarian cancer is sometimes called a 'silent' disease because early symptoms are often vague or nonspecific, such as bloating or mild abdominal discomfort, which can delay diagnosis until the cancer has spread within the abdomen. As a result, a substantial proportion of patients are diagnosed at an advanced stage, making coordinated surgical and medical oncology care particularly important.
Inherited mutations in genes such as BRCA1 and BRCA2 significantly increase the risk of developing ovarian cancer and also influence treatment selection, since BRCA-mutant tumors often respond especially well to PARP inhibitor therapy. Because of this, genetic counseling and testing have become a routine and important part of ovarian cancer care.
Types and Subtypes
Ovarian cancer includes several histologic subtypes with different behavior, molecular drivers, and treatment implications.
Symptoms and Signs
Early ovarian cancer often produces no symptoms or only vague, nonspecific complaints, which is why persistent new symptoms should prompt evaluation rather than be dismissed.
Causes and Risk Factors
Ovarian cancer risk is influenced by a combination of genetic, reproductive, and other factors, though many patients have no identifiable risk factor beyond age.
Diagnosis and Investigations
Diagnosing ovarian cancer typically involves a combination of imaging, blood tests, and tissue sampling, often confirmed at the time of surgery.
Disease Staging and Risk Stratification
Ovarian cancer is staged using the FIGO (International Federation of Gynecology and Obstetrics) system, which closely parallels TNM staging and reflects the extent of disease at the time of surgery.
Standard Treatment Options
Treatment of ovarian cancer typically combines surgery and chemotherapy, with the specific sequence and intensity tailored to disease stage and the patient's overall health.
Advanced and Emerging Treatment Options
Several targeted and novel therapies have changed the treatment landscape for ovarian cancer, particularly for patients with BRCA mutations or homologous recombination deficiency.
Targeted
PARP Inhibitors
Approved as maintenance therapy, particularly effective in BRCA-mutant and homologous recombination-deficient tumors.
Targeted
Bevacizumab (Anti-Angiogenic Therapy)
An antibody targeting tumor blood vessel formation, used in combination with chemotherapy and as maintenance therapy.
Immunotherapy
Immune Checkpoint Inhibitor Combinations
Being studied in clinical trials, particularly in combination with other agents, for select ovarian cancer subgroups.
Targeted
Antibody-Drug Conjugates (ADCs)
An emerging class of targeted agents being evaluated in recurrent ovarian cancer, including in tumors expressing specific surface markers such as folate receptor alpha.
Precision Medicine
Tumor Genomic Profiling-Guided Therapy
Molecular testing can identify additional actionable alterations that may open access to targeted agents or relevant clinical trials.
Biomarkers and Precision Medicine
Biomarker testing plays a central role in ovarian cancer management, guiding both prognosis and treatment selection.
When a Second Opinion May Be Important
Given the complexity of ovarian cancer surgery and the rapidly evolving landscape of targeted therapy, a second opinion can be particularly valuable at key decision points.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in ovarian cancer varies considerably based on stage at diagnosis, tumor subtype, genetic features, and response to initial treatment, and is best discussed individually with the treating oncology team.
Supportive Care and Living With Ovarian Cancer
Supportive care addresses the physical and emotional impact of ovarian cancer and its treatment across the full course of the disease.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with ovarian cancer access expert review of pathology, genetic testing, and imaging, coordinate second opinions, and explore PARP inhibitor, targeted therapy, and clinical trial options worldwide.
Get a free case reviewFrequently Asked Questions
Ovarian cancer is a cancer arising in the ovaries or, in many cases of the most common subtype, originating in the fallopian tube before involving the ovary, and it includes several distinct histologic subtypes.
Early signs are often vague, such as persistent bloating, pelvic discomfort, or feeling full quickly when eating, which is why ovarian cancer is sometimes diagnosed at a later stage.
Women with BRCA1 or BRCA2 mutations, a family history of ovarian or breast cancer, or a history of endometriosis are at increased risk, though most cases occur without a known strong risk factor.
Diagnosis typically involves imaging, the CA-125 blood test, and tissue confirmation, often established at the time of surgery, along with genetic testing for BRCA and related genes.
Standard treatment usually combines debulking surgery with platinum and taxane-based chemotherapy, often followed by PARP inhibitor or bevacizumab maintenance therapy.
BRCA mutations are associated with greater sensitivity to platinum chemotherapy and PARP inhibitors, which are often used as maintenance therapy in BRCA-mutant ovarian cancer.
Treatment for recurrent disease depends on how the cancer responded previously to platinum chemotherapy, and may include further chemotherapy, targeted therapy, or clinical trial participation.
Yes, active research includes antibody-drug conjugates, immunotherapy combinations, and next-generation PARP inhibitor strategies, particularly for recurrent or platinum-resistant disease.
Stage at diagnosis, the amount of residual disease after surgery, BRCA or HRD status, and response to initial chemotherapy are among the most important factors influencing outcomes.
Yes. CancerFax can help you submit your pathology, imaging, and genetic testing reports for specialist review, coordinate a second opinion, and explore access to PARP inhibitors, targeted therapies, and clinical trials, including cross-border care coordination where needed.
Get Expert Guidance for Ovarian Cancer
Connect with gynecologic oncology specialists to review your diagnosis and discuss surgical, chemotherapy, and targeted therapy options.